CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CING CINGULATE INC.

Market Closed 03-28 16:00:00 EDT

4.35

+0.00

0.00%

盘后4.10

-0.25-5.75%

19:58 EDT

High4.35	Low3.95	Vol97.11K
Open4.22	D1 Closing4.35	Amplitude9.20%
Mkt Cap15.87M	Tradable Cap15.83M	Total Shares3.65M
T/O403.92K	T/O Rate2.67%	Tradable Shares3.64M
P/B1.32	ROE-273.82%	EPS-22.31
52wk High20.83	52wk Low1.80	P/E-0.20
Dividend0.00	Div.Yield0.00	ROA-104.33%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CING","market":"US","secType":"STK","nameCN":"CINGULATE INC.","latestPrice":4.35,"timestamp":1743192000000,"preClose":4.35,"halted":0,"volume":97106,"hourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.35,"latestTime":"19:58 EDT","volume":253,"amount":1038.05,"timestamp":1743206314721},"delay":0,"floatShares":3638600,"shares":3647700,"eps":-22.30732,"marketStatus":"Market Closed","change":0,"latestTime":"03-28 16:00:00 EDT","open":4.22,"high":4.35,"low":3.95,"amount":403919.35978959996,"amplitude":0.091954,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-22.30732,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"listingDate":1633579200000,"exchange":"NASDAQ","adjPreClose":4.35,"preHourTrading":{"tag":"盘前","latestPrice":4.11,"preClose":4.35,"latestTime":"08:04 EDT","volume":269,"amount":1127.059966,"timestamp":1743163477916},"postHourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.35,"latestTime":"19:58 EDT","volume":253,"amount":1038.05,"timestamp":1743206314721},"volumeRatio":0.970237},"requestUrl":"/m/hq/s/CING/wiki","defaultTab":"wiki","newsList":[{"id":"2522960055","title":"Cingulate Inc. Reports 2024 Financial and Development Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2522960055","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522960055?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 12:02","pubTimestamp":1743134547,"startTime":"0","endTime":"0","summary":"Cingulate, Inc. ( ($CING) ) has released its Q4 earnings. Here is a breakdown of the information Cingulate, Inc. presented to its investors. Cingul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-inc-reports-2024-financial-and-development-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-inc-reports-2024-financial-and-development-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2522563983","title":"Cingulate Q4 Net loss $(6.1)M Up From $(6.9)M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2522563983","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522563983?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 05:10","pubTimestamp":1743023404,"startTime":"0","endTime":"0","summary":"Cingulate Q4 Net loss $(6.1)M Up From $(6.9)M YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44504639/cingulate-q4-net-loss-6-1-m-up-from-6-9-m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CING"],"gpt_icon":0},{"id":"2522416355","title":"Press Release: Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2522416355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522416355?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 05:00","pubTimestamp":1743022800,"startTime":"0","endTime":"0","summary":"Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved. In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025. $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission. \"The capital raised over the past year has allowed us to strengthen our balance sheet and complete all required clinical trials for NDA submission for CTx-1301. We look forward to meeting with the FDA next week, submitting our new drug application this summer, and, assuming approval by the FDA, bringing to market the first, true, once-daily stimulant medication to treat ADHD over the entire active day,\" said Cingulate Chairman and CEO Shane J Schaffer.and adolescent studies -- a fixed dose study and a dose optimization. treatment emergent adverse events and confirming that the safety profile. and pediatric safety data will be prepared and included i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4099","BK4007","CING","BK4588","BK4139","TM","03160","BK4555","BK4585","BK4604"],"gpt_icon":0},{"id":"2518922748","title":"CING: April Pre-NDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2518922748","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518922748?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 17:40","pubTimestamp":1741599600,"startTime":"0","endTime":"0","summary":"Since the report of third quarter results, Cingulate, Inc.  has executed a $5 million capital raise, completed its fast-fed study and reported safety results from its Phase III trials. As we move down the home stretch towards the FDA submission, Cingulate has a pre-new drug application  meeting scheduled for early April and anticipates filing its NDA with the agency by mid-2025. We also expect to see further safety data from the consolidated Phase III studies at an upcoming but as yet unidentified scientific conference.The pathway forward for FDA submission includes several parallel efforts which include updating stability data on 2024 batches of CTx-1301, completing the analysis of the fast fed study and attendance at the pre-NDA meeting with the FDA in early April. Notes from the meeting are expected about a month later, which will provide final details required for completing the NDA. NDA submission is expected by mid-2025. We anticipate a 10-to-12-month turnaround time by the agenc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cing-april-pre-nda-meeting-094000188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4023","CING","CMAX","BK4503","BK4196","BK4535","API","BK4181","BK4218","BK4007","BK4551","CINGW"],"gpt_icon":0},{"id":"2517859394","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517859394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517859394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:00","pubTimestamp":1741345200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Algonquin Pwr & Utl                              4Q       .09       BMO. ·Asana Inc. Class A                              4Q      (.01)  4:05 PM. ·Auna S.A. Class A                               4Q       .15       AMC. ·Vail Resorts Inc.                                2Q      6.29   4:05 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTMD","AUNA","DRRX","KALV","LRMR","EVEX","ATLC","VTS","LMB","ZVRA","CHRS","AEO","EWCZ","BBCP","ARCO","AMRN","MGTX","DKS","DRUG","AURA","NOA","BWMN","ORCL","WEST","FTCI","CINT","LEN.B","ACET","GECC","MOMO","SFIX","TBRG","MYPS","BNTX","LE","CING","KRMD","SSP","ADBE","BDTX","NKTR","FERG","HLLY","CVGW","URGN","BW","ASRT","CIEN","CDTX"],"gpt_icon":1},{"id":"2517154709","title":"Cingulate Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154709","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154709?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:44","pubTimestamp":1741265040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CING/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 07:44 ET (12:44 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING"],"gpt_icon":0},{"id":"2517944262","title":"Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517944262?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 00:45","pubTimestamp":1741193132,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Cingulate Inc (CING – Research Report), with a price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-prospects-for-cingulate-inc-buy-rating-backed-by-positive-phase-3-results-and-market-potential-of-ctx-1301?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-prospects-for-cingulate-inc-buy-rating-backed-by-positive-phase-3-results-and-market-potential-of-ctx-1301?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING"],"gpt_icon":0},{"id":"2517914798","title":"Roth MKM Reaffirms Their Buy Rating on Cingulate Inc (CING)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517914798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517914798?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:37","pubTimestamp":1741181832,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Cingulate Inc (CING – Research Report) today and set a price target of $12.00. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-cingulate-inc-cing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-cingulate-inc-cing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING"],"gpt_icon":0},{"id":"2516677738","title":"Cingulate Inc. Advances Towards FDA Approval for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677738","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516677738?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:29","pubTimestamp":1741098563,"startTime":"0","endTime":"0","summary":"An update from Cingulate Inc ( ($CING) ) is now available. On March 4, 2025, Cingulate Inc. announced the safety results from its final Phase 3 tri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-inc-advances-towards-fda-approval-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-inc-advances-towards-fda-approval-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CING"],"gpt_icon":0},{"id":"2516521674","title":"Cingulate reports safety results from final Phase 3 trials for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2516521674","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516521674?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:07","pubTimestamp":1741097232,"startTime":"0","endTime":"0","summary":"Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-reports-safety-results-from-final-phase-3-trials-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-reports-safety-results-from-final-phase-3-trials-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","CING","ABVC"],"gpt_icon":0},{"id":"2516710026","title":"BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2516710026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516710026?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:05","pubTimestamp":1741097119,"startTime":"0","endTime":"0","summary":"BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 March 4 (Reuters) - Cingulate Inc CING.O:CINGULATE REPORTS SAFETY RESULTS FROM FINAL PHASE 3 TRIALS FOR LE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA1BQKMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007","CINGW"],"gpt_icon":0},{"id":"2516967121","title":"Cingulate Reports Safety Results From Final Phase 3 Trials for Lead Adhd Asset Ctx-1301: on Track to File for FDA Approval Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516967121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516967121?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:00","pubTimestamp":1741096802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA1BQKMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CINGW","CING","BK4007"],"gpt_icon":0},{"id":"2516671786","title":"Cingulate Inc - No Serious Adverse Events Reported in Ctx-1301 Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516671786?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:00","pubTimestamp":1741096802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA1BQKMZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CING","BK4007","CINGW"],"gpt_icon":0},{"id":"2516674892","title":"Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674892","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674892?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY, Kan.,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036578/0/en/Cingulate-Reports-Safety-Results-from-Final-Phase-3-Trials-for-Lead-ADHD-Asset-CTx-1301-On-Track-to-File-for-FDA-Approval-Mid-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","ABVC","BK4023","ADHD","BK4007","BK4503","BK4139","BK4551","BK4535","API"],"gpt_icon":0},{"id":"2508176293","title":"Cingulate Inc - Charge Against CEO Schaffer  Dismissed","url":"https://stock-news.laohu8.com/highlight/detail?id=2508176293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508176293?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 06:19","pubTimestamp":1738621163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OU0J2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2507647533","title":"Cingulate Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647533","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647533?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 20:03","pubTimestamp":1738238580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CING/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 07:03 ET (12:03 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING"],"gpt_icon":0},{"id":"2507641811","title":"Cingulate price target adjusted to $20 from $8 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2507641811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507641811?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 19:17","pubTimestamp":1738235832,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Cingulate (CING) to $20 from $8 and keeps a Buy rating on the shares to reflect the recent revers...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-price-target-adjusted-to-20-from-8-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-price-target-adjusted-to-20-from-8-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING"],"gpt_icon":0},{"id":"2502864260","title":"Roth MKM Starts Cingulate With Buy Rating, $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2502864260","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502864260?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 22:30","pubTimestamp":1736519435,"startTime":"0","endTime":"0","summary":"Roth MKM Starts Cingulate With Buy Rating, $12 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CING"],"gpt_icon":0},{"id":"2502555298","title":"Cingulate initiated with a Buy at Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2502555298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502555298?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 18:41","pubTimestamp":1736505678,"startTime":"0","endTime":"0","summary":"Roth MKM initiated coverage of Cingulate (CING) with a Buy rating and $12 price target The firm’s optimism is driven by CTx-1301’s Phase 3 data dem...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-initiated-with-a-buy-at-roth-mkm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-initiated-with-a-buy-at-roth-mkm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CING"],"gpt_icon":0},{"id":"2502853809","title":"“Buy Rating for Cingulate Inc.: Promising Phase 3 Data and Strong Financial Outlook”","url":"https://stock-news.laohu8.com/highlight/detail?id=2502853809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502853809?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 18:28","pubTimestamp":1736504886,"startTime":"0","endTime":"0","summary":"Cingulate Inc (CING) has received a new Buy rating, initiated by Roth MKM analyst, Boobalan Pachaiyappan. Boobalan Pachaiyappan has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-cingulate-inc-promising-phase-3-data-and-strong-financial-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-cingulate-inc-promising-phase-3-data-and-strong-financial-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cingulate.com","stockEarnings":[{"period":"1week","weight":0.0985},{"period":"1month","weight":0.0164},{"period":"3month","weight":-0.09},{"period":"6month","weight":-0.1352},{"period":"1year","weight":-0.6705},{"period":"ytd","weight":-0.1176}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.260215},{"month":2,"riseRate":0.25,"avgChangeRate":-0.006109},{"month":3,"riseRate":0.5,"avgChangeRate":-0.049607},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.082482},{"month":5,"riseRate":0,"avgChangeRate":-0.240081},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.060694},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.164627},{"month":8,"riseRate":1,"avgChangeRate":0.47866},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.202848},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.194193},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.090852},{"month":12,"riseRate":1,"avgChangeRate":0.119395}],"exchange":"NASDAQ","name":"CINGULATE INC.","nameEN":"CINGULATE INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CINGULATE INC.,CING,CINGULATE INC.股票,CINGULATE INC.股票老虎,CINGULATE INC.股票老虎国际,CINGULATE INC.行情,CINGULATE INC.股票行情,CINGULATE INC.股价,CINGULATE INC.股市,CINGULATE INC.股票价格,CINGULATE INC.股票交易,CINGULATE INC.股票购买,CINGULATE INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}